Abstract: The present invention is in the fields of biotechnology, protein purification and crystallization, x-ray diffraction analysis, three-dimensional computer molecular modelling and rational drug design. The invention is directed to the Liver X receptor and ligands for this receptor, and in particular to crystalline Liver X receptor beta (LXR?) and to methods of identifying ligands utilizing LXR?, as well as to compounds, compositions and methods for selecting, making, and using therapeutic or diagnostic agents having LXR? modulating or binding activity.

Abstract: A system and method for generating a mask layout file to eliminate antenna effects in an integrated circuit are disclosed. The method includes analyzing a pattern in a mask layout file to identify a region including an antenna ratio less than a first design rule. A feature located in the identified region is moved based on a second design rule from a first position to a second position in the mask layout file. A grounding feature is placed in the space and automatically connected to a gate feature in the mask layout file such that the antenna ratio is increased to greater than or approximately equal to the first design rule.

Abstract: The present invention is directed to crystals comprising at least part of the estrogen receptor &agr; (ER&agr;) ligand binding domain, optionally bound to a ligand. The present invention is also directed to ligands that bind to ER receptors, and method of designing them. The present invention is also directed to a homology model of the ER&bgr; receptor.

Abstract: The present invention is directed to crystals of ER&bgr; ligand binding domain complexed with (1) N-(n-butyl)-11-[3,17&bgr;-dihydroxyestra-1,3,5(10)-trien-7&agr;-yl]N-methylundecanamide; estradiol and a peptide comprising the amino acid sequence LXXLL; or 17-epiestriol and a peptide comprising the amino acid sequence LXXLL.

Abstract: The application relates to a crystal comprising at least 150 amino acid residues of the estrogen receptor-&bgr; (ER&bgr;) ligand binding domain complexed with a ligand which is an antagonist or a partial agonist.

Abstract: A mammal intestinal hormone precursor having the following peptide structure: His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-L-M-Ala-Arg-Leu-Gl n -Arg-Leu-Leu-Gln-Gly-Leu-Val-Gly-N-O, wherein L is Glu or Asp, M is Gly or Ser, and N and O are selected from Lys and Arg; compositions containing such precursor and a method of stimulating pancreatic secretion.

Abstract: A human intestinal hormone having the following peptide structure: His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Le u-Gln-Arg-Leu-Gln-Gly-Leu-Val-NH.sub. 2 ; compositions containing such hormone; and a method of stimulating pancreatic secretion.